NZ526350A - Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol - Google Patents
Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcoholInfo
- Publication number
- NZ526350A NZ526350A NZ52635003A NZ52635003A NZ526350A NZ 526350 A NZ526350 A NZ 526350A NZ 52635003 A NZ52635003 A NZ 52635003A NZ 52635003 A NZ52635003 A NZ 52635003A NZ 526350 A NZ526350 A NZ 526350A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- present
- range
- amino
- vitamin
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An anti-ageing composition suitable for administrating to warm blooded animals including: one or more mono, di and/or trivalent metal salts, one or more amino acids, an amino alcohol and a vitamin B complex. Preferably the amino alcohol is selected from diethyl amino ethanol and dimethyl amino ethanol, the metals salts are selected from potassium, copper, calcium, manganese, molybdenum, selenium, vanadium, zinc, chromium, vanadium, the amino acid is selected from glutamine, arginine, lysine, orthine, proline, and histidine and the vitamin B complex is selected from para amino bezoic aicd, B1 (thiamin), B2 (riboflavin), B3, B5, B6 (pyridoxine) and B12 (cobalamin). The composition can also further comprise components including L-Taurine, inositol, choline, heseperidine, an oligopeptide, resveratrol, folic acid, biotin, vitamin D, vitamin A, ginko biloba extract, lycopene, proanthocyanidin, black seed extract, bromelain, lipase, catalese, colloidal silica, iodine and an immuno-stimulant.
Description
New Zealand Paient Spedficaiion for Paient Number 526350
Patents Form # 5
526 3 5 o
NEW ZEALAND
Patents Act 1953
COMPLETE SPECIFICATION
TITLE:
Anti-Aging Compositions
I, AL-SHAKARCHI, A. Munem Mohammad Daoud
Address: 4 Landsberg Way, Windsor Park, Mairangi Bay, Auckland, New Zealand Nationality: A Citizen of New Zealand do hereby declare the invention for which I pray that a patent may be granted to me and the method by which it is to be performed, to be particularly described in and by the following statement:
-1
jtellectual office of n.z luuw
RECEIVED
PF05.JWP
FEE CODE 1050
AN ANTI-AGEING ORAL COMPOSITION
FIELD OF THE INVENTION
The present invention relates to an anti-ageing oral composition, in particular, but not 5 exclusively to a dietary composition and methods of using such compositions.
BACKGROUND
The ageing process is believed to relate to the failure of cell components such as the cell nucleus to continue to replicate otherwise healthy cells. This is believed to occur as a result 10 of damage which occurs to essential cell components caused by drops in levels of key chemical agents with age.
These key chemical agents form part of the cellular liquid. This constitutes the extra-cellular and intra-cellular fluid which acts to nourish the extra-cellular matrix, such as tissue and nerves, and the intra-cellular matrix which comprises the inner structure of the cells, 15 including the cell nucleus and the mitochondria which are the energy producing elements within every living cell.
Accordingly it is essential to maintain, within the cellular liquid, high levels of these key agents such as antioxidants, hormonal precursors, RNA, DNA and other agents which otherwise decrease with age.
Accordingly, by vitalising, and continually revitalising, the cellular liquid, essential components of cells of the human body will not sense "environmental changes" which they have been genetically taught to associate with the ageing process.
Reductions in such key chemical agents are believed to cause damage to the RNA and DNA in each cell nucleus which thereby reduces the ability of the cell to reproduce itself which 25 ultimately brings on the ageing process. Accordingly, the essential problem in stopping the ageing process is that of maintaining appropriate levels of key metabolic agents so that the genetic material within each cell will not become damaged or otherwise lose efficiency.
301083nzprov.N02/WJ/ca
Also of importance in halting the ageing process is maintaining the health of the cell surface membrane which is the surface which delineates the extra-from the intra cellular fluid.
The cell surface membrane mediates flow of essential metabolic agents between the extra-and intra cellular fluid through the function of receptor sites upon the surface membrane of 5 each cell. Numerous types of receptor sites exist which regulate a wide variety of amino acids, hormonal and anti-oxidant transfer between the extra, and intra cellular fluids. Also, the cell surface membrane plays an essential role in the function of so-called ionic pathways between the extra and intra cellular fluid, these facilitating the movement of certain agents, such as minerals, which move electro statically between the extra and intra cellular fluid.
The present invention may, accordingly, be viewed in terms of an oral supplementation program designed to restore the integrity of the cellular soup, to neutralize efficiency-impeding end products of metabolism which relate to the ageing process, and to supply higher, more useful levels of anti-oxidants to better combat otherwise damaging free radicals. With such reduction of free radicals, essential hormonal pre-precursors, including 15 neural hormonal precursors, which are essential to the health of brain, related glands and the central nervous system, and the building blocks of DNA, are preserved. The instant oral therapy program is therefore designed to supplement all cell matrices to thereby ensure provision of necessary hormonal precursors, enzymes, and other necessary building blocks of each cell.
This invention more particularly relates to a multi-agent bi-daily capsules/or/ tablets which allows the supply of the equivalent of numerous vitamins, minerals, amino acids, enzymes, supplements, neuro-hormonal precursors, with phytoextracts from plants and precursors for augmenting DNA repair and limiting DNA damage. This invention provides the key vitamins, amino acids, minerals, and several components of plants and algae which are not 25 obtainable through the average daily diet.
Another key component of the present oral therapy are pH balancing factors. It has been found that normal cellular pH, i.e., should be in the range of 6.45 to 7.5. It has been found that if the extra or intra cellular fluid is either too acid (above said range) or too basic (below the range); the entire metabolic process will function suboptimally. Accordingly, the present 30 oral supplementation, through its provision of blue/green algae's ensures the maintenance of
301083nzprov.N02 AVJ/ca
a proper pH range in the cellular liquid. It has, more particularly, been determined that in the absence of proper pH, the ability of the cell to properly reproduce polypeptide and proteins is impacted as is the functions of the cell regeneration and of signal transudation, i.e., production of the chemical messengers which enable cells and tissues to communicate with 5 each other.
It is to be understood that the present oral supplementation program is designed to provide, at times corresponding to the body's natural bio-rhythm, essential pH balancing agents, hormonal precursors and DNA/RNA protecting agents. The maintenance of a proper level of hormones and hormone precursors is essential to maintain the ability of the body to produce 10 such essential agents as insulin growth factor (IGF), the function of which is to provide growth hormones which, among other functions, stabilize the body against insulin reaction. The growth hormone is further responsible for enabling amino acids and polypeptides with the cell to reach the cell nucleus to thereby enable the cell to properly divide and regenerate itself. IGF also enables polypeptides and amino acids to mediate the cellular membrane for 15 the proper nourishment of the cell and helps other agents reach the intracellular fluid. Accordingly, hormone precursors are essential to optimise the body's hormonal response to ageing. More particularly, the most significant hormones, which relate to ageing, are, believed to be released by the pituitary and thymus glands. As such, through the present oral supplementation program, key hormonal components are strategically enabled; thereby 20 regulating age related hormones and hormone precursors.
A further benefit of the instant oral supplemental program is that of augmenting the key enzymes which aid in human digestion. That is, protecting and assisting the function of the stomach and intestinal system. It has been found that an individual that ingests all necessary metabolic agents will not necessarily achieve the above set forth anti-ageing benefits if the 25 digestive tract is unable to efficiently process such agents. Accordingly, an essential aspect of the present system is that of enhancing those enzymes which are essential to human digestion to assure that an individual employing the present system will be able to digest the same in an efficient way so that the anticipated benefits of the system can be realised.
In addition, it has been found that, with age, the efficiency of the intestine or gut will 30 deteriorate. Accordingly, the ability to utilise nutrients in an efficient manner drops as a function of age, thereby accelerating the ageing process. Thus, the present inventor has
301083nzprov.N02/WJ/ca
discovered that no program of nutrient and anti-free radical supplementation can be successful unless those enzymes which aid digestion and which otherwise protect the intestinal tract are a part of such a system.
The prior art, as is known to the inventor, consists of individual and multiple vitamin and 5 supplements which only give partial benefits relative to those of the instant invention. None of the vitamin or mineral supplements, or other prior art known to the inventor, addresses the problems as presented above. That is, no other vitamin or mineral supplement system that supplements in a manner synchronous with the bio-rhythmic demands which dictate the timing of biologic need for specific doses of supplements which are required for specific 10 times in the cell repair cycle
On the cellular level, aspartyl and asparaginyl residues are prominent sites of age related damage in proteins. These damaged sites have been characterised in a variety of proteins, but are particularly common in the long-lived proteins. Enzymatic mechanisms for reversing damage to DNA are well established and have been shown to be essential for extended 15 lifespan.
The instant method of metabolic adjuvanation and cellular repair includes the steps of
(a) Determining the daily vitamin, mineral, amino, neurohormonal precursor, and enzymatic needs of a subject; (b) ascertaining those periods of said subject's daily biocycle at which each vitamin, mineral, amino acids, neurohormonal precursor and enzymatic compound can 20 be optimally absorbed; and (c) furnishing to the subject, at said periods, selected combinations and quantities of such vitamins, minerals, amino, neurohormonal precursors, and enzymes that are optimal, for each of such biocycle period, in a palatable comestible binder of suitable geometry. Therein resulting in therapeutically sustained levels of said components act to maximise the body's inherent biochemical pathways to thereby limit 25 damage otherwise caused by deficiencies during the normal ageing process.
The present invention also relates to a multi-agent bi-daily capsules, or tablets (vitamin, mineral, plant extracts, amino acids, neurochemical precursors, digestive enzymes and other agents), which supply key elements necessary for proper metabolization and function of the human body at times of the daily biocycle when the need for such specific agents exists.
301083nzprov.N02/WJ/ca
It is a further object of the invention to reduce the effect of ageing by increasing the digestive and metabolic capabilities of the body.
It is another object to provide a comprehensive vitamin; mineral and nutrient supplement system congruent with natural biorhythms to thereby maximise metabolization, proper 5 hormonal formation, release, and utilisation of the supplements of such a system.
It is a further object to provide appropriate acidity to both the extracullar and intracellular matrices.
In brief, the present invention alleviates and overcomes certain of the above-mentioned problems and shortcomings of the present state of the art through the discovery of novel 10 acceptable delivery systems for effectively treating and preventing ageing, and methods of using same.
STATEMENTS OF THE INVENTION
According to a first aspect of the present invention, there is provided an anti-ageing 15 composition suitable for administering to warm blooded animals including: one or more mono, di and/or trivalent metal salts; one or more amino acids; wherein the composition further comprises an amino alcohol and a vitamin B complex.
Preferably, the amino alcohol can be selected from the group comprising diethyl amino 20 ethanol and dimethyl amino ethanol.
Preferably, the vitamin B complex can be selected from the group comprising para amino benzoic acid, Bl, B2, B3, B5, B6 and B12.
Preferably, the composition further includes S-adenosyl - L methionine
301083nzprov.N02/Wjyca
Preferably, the composition farther includes gamma butyric acid.
Preferably, the or each mono valent metal salt can be selected from the group comprising potassium and copper.
Preferably, the or each di-valent metal salt can be selected from the group comprising calcium, copper, manganese, molybdenum, selenium, vanadium and zinc
Preferably, the trivalent metal salt can be selected from the group comprising chromium, vanadium and manganese.
Preferably, the or each amino acid can be selected from the group comprising glutamine, L-arginine, L-lysine, L-ornithine, L-proline and L-histidine.
Preferably, the composition further comprises L-Taurine.
Preferably, the composition further includes a growth factor.
More preferably still, the growth factor is inositol.
Preferably, the composition further includes at least one of the following: choline, heseperidine, an oligopeptide, L-glutathione, trans-resveratrol, folic acid, biotin as vitamin
301083nzprov.N02/WJ/ca
D3, vitamin A, Ginko biloba extract, lycopene, proanthocyanidin, folic acid, black seed extract, bromelain, lipase, catalese, colloidal silica, and/or iodine.
Preferably, the composition further includes an aliphatic alcohol.
More preferably still, the aliphatic alcohol is octacosanol.
Preferably, the composition further includes an immuno-stimulant.
More preferably still, the immuno-stimulant is acemannan.
Preferably, the amino alcohol is present in the range 3-23% w/v.
Preferably, the vitamin B complex is present in the range 0.5-15%w/v.
Preferably, S-adenosyl-L methionine is present in the range of l-8%w/v.
Preferably, the one or more mono, di and/or trivalent metal salts are present in the range of 3-15%w/v.
Preferably, colloidal silica is present in the range of 0.5-3%w/v.
301083nzprov.N02/WJ/ca
Preferably, iodine is present in the range of 1x10-4 - 5xl0-4w/v.
Preferably, di ethyl amino ethanol is present in the range of l-10%w/v.
Preferably, di-methyl amino ethanol is present in the range of l-10%w/v.
Preferably, choline is present in the range of l-5%w/v.
Preferably, inositol is present n the range of l-5%w/v.
Preferably, heseperidine is present in the range of 0.5-3%w/v.
Preferably, oligopeptide is present in the range of 0.1 - l%w/v.
Preferably, the aliphatic alcohol is present in the range of 0.01-0.1%w/v.
Preferably, the or each amino acid is present in the range of 15-35%w/v.
Preferably, gamma butyric acid is present in the range of l-5%w/v.
Preferably, L-Taurine is present in the range of l-8%w/v.
301083nzprov.N02/WJ/ca
Preferably, acemannan is present in the range of 3-9%w/v.
Preferably, trans resveratrol is present in the range of 0.05-1.5%w/v.
Preferably, vitamin E is present in the range of 0.5-2%w/v.
Preferably, folic acid is present in the range of 1.5xl0-4-3xl0-4w/v.
Preferably, biotin is present in the range of 1.5x10-4-3x10-4w/v.
I
Preferably, ginko biloba extract is present in the range of l-6%w/v.
Preferably, lycopene is present in the range of 0.1-2%w/v.
Preferably, grape seed extract is present in the range of 0.5-5%w/v.
Preferably, black seed extract is present in the range of l-3%w/v.
Preferably, bromelain is present in the range of 0.5-3%w/v.
301083nzprov.N02AVJ/ca
Preferably, lipase is present in the range of 0.5-3%w/v.
Preferably, catalese is present in the range of 0.1-2%w/v.
Preferably, the composition further includes an excipient.
More preferably still, the excipient is present in the range of 2-15%w/v.
Still more preferably, the composition is to be administered as a tablet and the excipient can 10 be selected from the group comprising: lactose, micro-crystaline cellulose, cellulose powder, hydroxypropylcellulose, magnesium stearate and silicon dioxide.
DESCRIPTION OF THE PREFERRED EMBODIMENT The present embodiment is shown by way of example only.
The following example is a preferred embodiment of the present invention and shows a composition in the form of an oral composition (tablet form) and the constituent components that go into making that composition. Of course, in alternative embodiments not described, any appropriate selection or combination of the component parts used in the formulation of the oral composition of the example given below could used to form alternative compositions, that could be oral compositions in the form of tablets or fluids or injectable compositions.
301083nzprov.N02/WJ/ca
Example:
Selenium (Selenomethionine) 1 mg
Chromium (Picolinate) 1 mg
Magnesium 50 mg
Potassium 25 mg
Colloidal Silica 25 mg
Calcium 50 mg
Copper 1 mg
Iodine 1 mg
Manganese 10 mg
Molybdenum 1 mg
Vanadium 1 mg
Zinc 10 mg ++++ 180 mg.
DEAE (diethylaminoethanol) 75 mg
DMAE (dimethylaminoethanol) 75 mg
Choline 50 mg
Inositol 50 mg
Heseperidine 20 mg
Oligopeptide 10 mg 285 mg
Octacosanol 5 mg
301083nzprov.N02/WJ/ca
Glutamine 100 mg
L-Arginine 50 mg
L-Lysine 50 mg 5 GABA (gamma-Butyric Acid) 50 mg
L-Glutathione 50 mg
L-Ornithine 50 mg
L-Proline 50 mg
L-Histidine + 75 mg
L-Taurine 75 mg 550 mg
S-adenosyl-L-methionine 50 mg
Substitution of Adenosine and Methionine for SAM Acemannan 100 mg
Trans-Resveratrol 15 mg 165 mg
(trans-3,5,4," -trihydroxystilbene)
PABA (para-aminobenzoic acid) 150 mg VitaminE (RRR-alpha-Tocopheryl) 30 mg 20 Vit. B1 10 mg
Vit. B2 10 mg
301083nzprov.N02/WJ/ca
Vit. B3 30 mg 230 mg
Vit. B5 30 mg
Vit. B6 30 mg
Vit. B12 0,1 mg.
Folic acid 0.5 mg
Biotin as 0.5 mg
Vit. D3 100 IU Vit.A 2 mg 64 mg
Ginkgo biloba extract 24/6 50 mg
Lycopene 10 mg Grape Seed extract (Proanthocyanidin) 40 mg
Black seed extract 50 mg 150 mg
Bromelain 20 mg
Lipase 20 mg
Catalese 10 mg 50 mg
= 1675 mg / day.
Plus 150 X 2 = 300 Excipients
301083nzprov.N02AVJ/ca
Excipients as follow:-
Lactose (e.g Hydrous 200) = 95 mg
Cellulose (Macrocrystalline, e.g. Cellulose 102) = 105mg
Cellulose powder(Sodium Carboxymethylcellulose) = 40 mg
Hydroxypropylcellulose = 25 mg.
Magnesium Stearate = 20 mg
Silicon Dioxide =15 mg
Plus 300 mg delivery system Plus 100 Energy system Plus 25 mg. coating
Total = 2400 mg / 2 = (Minimum) = 1200 mg/ Tablet
It is to be appreciated that all of these components can be used alone, but combined use of all of them in the manner described will further improve their effects.
Means and methods employed to produce tablets having the types of formulation described herein are known to the person skilled in the art and need not be discussed further in this specification.
301083nzprov.N02/WJ/ca
Claims (48)
1. An anti-ageing composition suitable for administering to warm blooded animals including: one or more mono, di and/or trivalent metal salts; one or more amino acids; wherein the composition further comprises an amino alcohol and a vitamin B complex. 5
2. A composition as claimed in claim 1 wherein the amino alcohol can be selected from the group comprising diethyl amino ethanol and dimethyl amino ethanol.
3. A composition as claimed in claim 1 or claim 2 wherein, the vitamin B complex can be selected from the group comprising para amino benzoic acid, Bl, B2, B3, B5, B6 and B12.
4. A composition as claimed in any preceding claim wherein, the composition further includes S-adenosyl - L methionine 15
5. A composition as claimed in any preceding claim wherein, the composition further includes gamma butyric acid.
6. A composition as claimed in any preceding claim wherein, the or each mono valent metal salt can be selected from the group comprising potassium and copper. 20
7. A composition as claimed in any preceding claim wherein, the or each di-valent metal salt can be selected from the group comprising calcium, copper, manganese, molybdenum, selenium, vanadium and zinc 301083nzprov.N02/WJ/ca -18-
8. A composition as claimed in any preceding claim wherein, the trivalent metal salt can be selected from the group comprising chromium, vanadium and manganese.
9. A composition as claimed in any preceding claim wherein, the or each amino acid can be selected from the group comprising glutamine, L-arginine, L-lysine, L-ornithine, L-proline and L-histidine.
10. A composition as claimed in any preceding claim wherein, the composition further comprises L-Taurine.
11. A composition as claimed in any preceding claim wherein, the composition further includes a growth factor.
12. A composition as claimed in claim 11 wherein, the growth factor is inositol.
13. A composition as claimed in any preceding claim wherein, the composition further includes at least one of the following: choline, heseperidine, an oligopeptide, L-glutathione, trans-resveratrol, folic acid, biotin as vitamin D3, vitamin A, Ginko biloba extract, lycopene, proanthocyanidin, folic acid, black seed extract, bromelain, lipase, catalese, colloidal silica, and/or iodine.
14. A composition as claimed in any preceding claim wherein, the composition further includes an aliphatic alcohol. 301083nzprov.N02/WJ/ca -19-
15. A composition as claimed in claim 14 wherein, the aliphatic alcohol is octacosanol.
16. A composition as claimed in any preceding claim wherein, the composition further includes an immuno-stimulant. 5
17. A composition as claimed in claim 16, wherein, the immuno-stimulant is acemannan.
18. A composition as claimed in any preceding claim wherein, the amino alcohol is present in the range 3-23% w/v.
19. A composition as claimed in any preceding claim wherein, the vitamin B complex is present in the range 0.5-15%w/v.
20. A composition as claimed in claim 4 wherein, S-adenosyl-L methionine is present in the range of l-8%w/v.
21. A composition as claimed in any preceding claim wherein, the one or more mono, di and/or trivalent metal salts are present in the range of 3-15%w/v. 20 22. A composition as claimed in any preceding claim wherein, colloidal silica is present in the range of 0.5-3%w/v.
^INmLEoTuAL PR0pERTY"l OFRCF OP (\|.2 29 JAN20W received 130108NZ Spec.docAVJ/ca -20-
23. A composition as claimed in any preceding claim wherein, iodine is present in the range of 1x10-4-5xl0-4w/v.
24. A composition as claimed in any preceding claim wherein, di ethyl amino ethanol is 5 present in the range of 1 -10%w/v.
25. A composition as claimed in any preceding claim wherein, di methyl amino ethanol is present in the range of 1 -10%w/v. 10
26. A composition as claimed in any preceding claim wherein, choline is present in the range of l-5%w/v.
27. A composition as claimed in any preceding claim wherein, inositol is present n the range of l-5%w/v. 15
28. A composition as claimed in any preceding claim wherein, heseperidine is present in the range of 0.5-3%w/v.
29. A composition as claimed in any preceding claim wherein, oligopeptide is present in the 20 range of 0.1-l%w/v.
30. A composition as claimed in claim 14 or 15 wherein, the aliphatic alcohol is present in the range of 0.01-0.l%w/v. OFFICE OF i\j.Z 130108NZ Spec.doc/WJ/ca 2 9 JAN 2004 received -21 -
31. A composition as claimed in any preceding claim wherein, the or each amino acid is present in the range of 15-35%w/v. 5
32. A composition as claimed in any preceding claim wherein, gamma butyric acid is present in the range of l-5%w/v.
33. A composition as claimed in any preceding claim wherein, L-Taurine is present in the range of l-8%w/v. 10
34. A composition as claimed in any preceding claim wherein, acemannan is present in the range of 3-9%w/v.
35. A composition as claimed in any preceding claim wherein, trans resveratrol is present in 15 the range of 0.05-1.5%w/v.
36. A composition as claimed in any preceding claim wherein, vitamin E is present in the range of 0.5-2%w/v. 20
37. A composition as claimed in any preceding claim wherein, folic acid is present in the range of 1.5x10-4-3x10-4w/v.
38. A composition as claimed in any preceding claim wherein, biotin is present in the range of 1.5x10-4-3x10-4w/v. 301083nzprov.N02/WJ/ca -22-
39. A composition as claimed in any preceding claim wherein, ginko biloba extract is present in the range of 1 -6%w/v.
40. A composition as claimed in any preceding claim wherein, lycopene is present in the range of 0.1-2%w/v.
41. A composition as claimed in any preceding claim wherein, grape seed extract is present in the range of 0.5-5%w/v.
42. A composition as claimed in any preceding claim wherein, black seed extract is present in the range of l-3%w/v.
43. A composition as claimed in any preceding claim wherein, bromelain is present in the range of 0.5-3%w/v.
44. A composition as claimed in any preceding claim wherein, lipase is present in the range of 0.5-3%w/v.
45. A composition as claimed in any preceding claim wherein, catalese is present in the range of 0.1-2%w/v.
46. A composition as claimed in any preceding claim wherein, an excipient is present in the range of 2-15%w/v. 301083nzprov.N02/WJ/ca -23 -
47. A composition as claimed in any preceding claim wherein, the composition further includes an excipient.
48. A composition as claimed in claim 47 wherein, the excipient can be selected from the group comprising: lactose, micro crystalinecellulose, cellulose powder, hydroxypropylcellulose, manesium stearate and silicon dioxide.. intellectual property office of im.z 2 9 JAN 2001 received 130108NZ Spec.doc/WJ/ca
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ52635003A NZ526350A (en) | 2003-06-09 | 2003-06-09 | Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ52635003A NZ526350A (en) | 2003-06-09 | 2003-06-09 | Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ526350A true NZ526350A (en) | 2004-10-29 |
Family
ID=33297579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ52635003A NZ526350A (en) | 2003-06-09 | 2003-06-09 | Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ526350A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008139314A1 (en) * | 2007-05-11 | 2008-11-20 | Horphag Research (Luxembourg) Holding Sa | Compositions and methods for treating joint disorders |
| WO2010132021A1 (en) | 2009-05-14 | 2010-11-18 | Hsiehs Biotech (Singapore) Pte Ltd | Lycopene and resveratrol dietary supplement |
| EP2218449A3 (en) * | 2004-11-15 | 2011-05-18 | Erasmus MC | Use of mannitol in anti ageing treatments and Selection of anti ageing compounds using non human animal models with mutations in the DNA repair mechanisms. |
| CN102366103A (en) * | 2011-10-29 | 2012-03-07 | 山西振东五和健康食品股份有限公司 | Food applicable to maintaining functions of middle-aged and old men |
| US20140213542A1 (en) * | 2011-08-12 | 2014-07-31 | Mitsubishi Gas Chemical Company, Inc. | Composition containing s-adenosyl-l-methionine with excellent storage stability |
| US20150044308A1 (en) * | 2012-02-15 | 2015-02-12 | Laboratec, S.L. | Pharmaceutical Composition for Treating Urinary Incontinence and Enuresis |
| FR3029418A1 (en) * | 2014-12-09 | 2016-06-10 | Michel Frey | COMPOSITION FOR SLOWING THE SIGNS OF PATHOLOGICAL OR PHYSIOLOGICAL AGING. |
| DE202016006697U1 (en) * | 2016-10-31 | 2017-06-30 | Kati Leopold | Mixture of substances to improve the mental and cognitive processes |
| WO2021008822A1 (en) | 2019-07-12 | 2021-01-21 | Unilever Plc | Topical compositions and methods of using same against mitochondrial fragmentation |
-
2003
- 2003-06-09 NZ NZ52635003A patent/NZ526350A/en unknown
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2218449A3 (en) * | 2004-11-15 | 2011-05-18 | Erasmus MC | Use of mannitol in anti ageing treatments and Selection of anti ageing compounds using non human animal models with mutations in the DNA repair mechanisms. |
| WO2008139314A1 (en) * | 2007-05-11 | 2008-11-20 | Horphag Research (Luxembourg) Holding Sa | Compositions and methods for treating joint disorders |
| WO2010132021A1 (en) | 2009-05-14 | 2010-11-18 | Hsiehs Biotech (Singapore) Pte Ltd | Lycopene and resveratrol dietary supplement |
| US9700629B2 (en) * | 2011-08-12 | 2017-07-11 | Mitsubishi Gas Chemical Company, Inc. | Composition containing S-adenosyl-L-methionine with excellent storage stability |
| US20140213542A1 (en) * | 2011-08-12 | 2014-07-31 | Mitsubishi Gas Chemical Company, Inc. | Composition containing s-adenosyl-l-methionine with excellent storage stability |
| CN102366103A (en) * | 2011-10-29 | 2012-03-07 | 山西振东五和健康食品股份有限公司 | Food applicable to maintaining functions of middle-aged and old men |
| CN102366103B (en) * | 2011-10-29 | 2012-12-05 | 山西振东五和健康食品股份有限公司 | Food applicable to maintaining functions of middle-aged and old men |
| US20150044308A1 (en) * | 2012-02-15 | 2015-02-12 | Laboratec, S.L. | Pharmaceutical Composition for Treating Urinary Incontinence and Enuresis |
| US9272011B2 (en) * | 2012-02-15 | 2016-03-01 | Laboratec, S.L. | Pharmaceutical composition for treating urinary incontinence and enuresis |
| FR3029418A1 (en) * | 2014-12-09 | 2016-06-10 | Michel Frey | COMPOSITION FOR SLOWING THE SIGNS OF PATHOLOGICAL OR PHYSIOLOGICAL AGING. |
| WO2016092193A1 (en) * | 2014-12-09 | 2016-06-16 | Michel Frey | Composition for slowing cellular ageing, associated food supplement |
| DE202016006697U1 (en) * | 2016-10-31 | 2017-06-30 | Kati Leopold | Mixture of substances to improve the mental and cognitive processes |
| WO2021008822A1 (en) | 2019-07-12 | 2021-01-21 | Unilever Plc | Topical compositions and methods of using same against mitochondrial fragmentation |
| CN114126577A (en) * | 2019-07-12 | 2022-03-01 | 联合利华知识产权控股有限公司 | Topical compositions and methods of using same to resist mitochondrial fragmentation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5895652A (en) | Method of metabolic adjuvanation and cellular repair | |
| WO2004100896A2 (en) | Anti-aging nutritional supplement | |
| US20080031976A1 (en) | Multivitamin formulations for promoting healthy collagen, and methods of their use | |
| US20140308248A1 (en) | Dietary Supplement System for Multifunctional Anti-Aging Management and Method of Use | |
| US8334131B2 (en) | Formulations for promoting stem cell nutrition | |
| US20100124587A1 (en) | Creatine-containing vitamin and mineral composition | |
| Powell et al. | Effects of glycine supplementation at varying levels of methionine and cystine on the growth performance of broilers fed reduced crude protein diets | |
| CN109045037A (en) | It is a kind of to promote the anti-apolexis composition of cozymase, preparation and preparation method thereof | |
| NZ526350A (en) | Anti-aging compositions comprising an amino acid, vitamin B complex, metal salt and an amino alcohol | |
| US20140212388A1 (en) | Composition For Cosmetic And Health Improvement | |
| US20210023180A1 (en) | Vitamins and Alpha Keto Acid Compositions for Use in a Treatment Program for Chronic Kidney Disease Patients | |
| US20240285704A1 (en) | Compositions comprising organic mineral chelates, niacinamide, and hemp oil and uses thereof for neuroprotection, cardioprotection, detoxification, immune support, and anti-aging | |
| EP0714276B1 (en) | Composition against hair loss and brittle nails | |
| EP3799724B1 (en) | Vitamins and alpha keto acid compositions for use in a treatment program for chronic kidney disease patients | |
| Liu et al. | The effects of dietary sulfur amino acids on serum biochemical variables, mucosal amino acid profiles, and intestinal inflammation in weaning piglets | |
| JP2015007092A (en) | Multivitamin/mineral formulation to combat effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without negative side effects of mega dose nutritional supplement | |
| GB2585619A (en) | A supplement | |
| Powell et al. | The interactive effects of glycine, total sulfur amino acids, and lysine supplementation to corn-soybean meal diets on growth performance and serum uric acid and urea concentrations in broilers | |
| US20100331286A1 (en) | Combination therapy for treatment of bone and mineral disorders for patients with impaired renal function | |
| US20110177010A1 (en) | Vitamin preparation | |
| US20130172299A1 (en) | Combination Therapy for Treatment of Bone and Mineral Disorders for Patients with Impaired Renal Function | |
| Kim et al. | Effect of dietary medicinal plant by-products on egg production and egg quality in laying hens | |
| WO2009033250A1 (en) | Composition and method for increasing the anabolic state of muscle cells | |
| CA2598786C (en) | Composition and method for increasing the anabolic state of muscle cells | |
| US12109254B2 (en) | Vitamins and alpha keto acid compositions for use in a treatment program for chronic kidney disease patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |